(R)-methyl 3-azido-2-hydroxypropanoate | 159871-49-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-methyl 3-azido-2-hydroxypropanoate
• 英文别名: methyl (2R)-3-azido-2-hydroxypropanoate
• CAS: 159871-49-5
• 化学式: C₄H₇N₃O₃
• 分子量: 145.118
• InChiKey: WXPNOMLJKFTBSM-GSVOUGTGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  60.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-methyl 3-azido-2-hydroxypropanoate 在 甲醇 、 sodium hydroxide 、 水 、 盐酸 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 (R)-2-羟基-3-叠氮丙酸
  参考文献：
  名称：

  WO2006/127961

  摘要：

  公开号：
• 作为产物：
  描述：

  (R)-缩水甘油酸甲酯 在 sodium azide 、 氯化铵 作用下， 以 甲醇 、 水 为溶剂， 反应 10.0h， 以69%的产率得到(R)-methyl 3-azido-2-hydroxypropanoate
  参考文献：
  名称：

  WO2006/127961

  摘要：

  公开号：

文献信息

• A safe and convenient method for the preparation of triflyl azide, and its use in diazo transfer reactions to primary amines
  作者：Alexander Titz、Zorana Radic、Oliver Schwardt、Beat Ernst

  DOI：10.1016/j.tetlet.2006.01.157

  日期：2006.4

  A safe and convenient method for the copper(II)-catalyzed diazo transfer from triflyl azide to primary amines is reported. By replacing CH2Cl2 by toluene the formation of hazardous side products, for example, azido-chloromethane and diazidomethane can be avoided.

  报道了一种安全方便的铜（II）催化重氮从三氟叠氮化物转移到伯胺的方法。通过用甲苯代替CH 2 Cl 2，可以避免形成危险的副产物，例如叠氮基氯甲烷和重氮基甲烷。
• Enhanced indolinone based protein kinase inhibitors
  申请人：Liang Congxin

  公开号：US20060287381A1

  公开（公告）日：2006-12-21

  Hydroxy carboxy pyrrolyl-indolinone derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer. More particularly, alpha-hydroxy-omega-(2-oxo-indolylidenemethyl-pyrrole-3′-carbonyl) amino alkanoic acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases with respect to their corresponding beta-hydroxy-omega-(2-oxo-indolylidenemethyl-pyrrole-3′-carbonyl) amino alkanoic acid and amide derivatives and are useful in treating disorders related to abnormal protein kinase activities such as cancer.

  羟基羧基吡咯基吲哚酮衍生物具有增强和意外的药物特性，可以作为蛋白激酶抑制剂，用于治疗与异常蛋白激酶活性相关的疾病，如癌症。特别地，α-羟基-ω-（2-氧代吲哚亚甲基吡咯-3'-羧酰基）氨基脂肪酸和酰胺衍生物具有增强和意外的药物特性，可作为蛋白激酶抑制剂，相对于其相应的β-羟基-ω-（2-氧代吲哚亚甲基吡咯-3'-羧酰基）氨基脂肪酸和酰胺衍生物，用于治疗与异常蛋白激酶活性相关的疾病，如癌症。
• Enhanced Indolinone Based Protein Kinase Inhibitors
  申请人：Liang Congxin

  公开号：US20100267719A1

  公开（公告）日：2010-10-21

  Alpha-hydroxy-omega-(2-oxo-indolylidenemethyl-pyrrole-3′-carbonyl)amino alkanoic acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.

  Alpha-hydroxy-omega-(2-oxo-indolylidenemethyl-pyrrole-3′-carbonyl)amino烷基酸和酰胺衍生物具有增强和意外的药物特性，可作为蛋白激酶抑制剂用于治疗与异常蛋白激酶活性相关的疾病，如癌症。
• US2014/256697
  申请人：——

  公开号：——

  公开（公告）日：——
• Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
  作者：Toshiaki Aoki、Hidenori Yoshizawa、Kenji Yamawaki、Katsuki Yokoo、Jun Sato、Shinya Hisakawa、Yasushi Hasegawa、Hiroki Kusano、Masayuki Sano、Hideki Sugimoto、Yasuhiro Nishitani、Takafumi Sato、Masakatsu Tsuji、Rio Nakamura、Toru Nishikawa、Yoshinori Yamano

  DOI：10.1016/j.ejmech.2018.06.014

  日期：2018.7

  The structure-activity relationship (SAR) for a novel series of catechol conjugated siderophore cephalosporins is described with their in vitro activities against multi-drug resistant Gram-negative pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae. Cefiderocol (3) was one of the best molecules which displayed well-balanced and potent activities against multi-drug resistant Gram-negative pathogens including carbapenem resistant bacteria among the prepared compounds with the modified C-7 side chain and the modified C-3 side chain. Cefiderocol (3) is a highly promising parenteral cephalosporin for the treatment of multi-drug resistant Gram-negative infection. (C) 2018 Elsevier Masson SAS. All rights reserved.